Regeneron Pharma Stock (US75886F1075): Analyst support keeps the shares in view

Regeneron Pharma is in focus on Monday after an Ad-hoc-News report said the analyst consensus price target sits at about $792.65, well above the recent share price.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 15, 2026 at 10:38 PM ET. Details in the imprint.

Regeneron Pharma is in focus on Monday after a fresh analyst roundup pointed to continued Wall Street support for the stock. Ad-hoc-News reported that MarketBeat's current consensus price target stands at about $792.65 per share, while the latest quoted level remains well below that mark.

What is driving the move in the stock

The same report said MarketBeat counts 27 analysts covering Regeneron and labels the stock's aggregated rating as "moderate buy." That combination matters because it shows the current debate is not about whether the company has coverage, but about how much upside analysts still see from here.

For US retail investors, that is a straightforward signal that the name remains closely followed on the analyst side even on a quiet trading day. Regeneron trades on Nasdaq under the ticker REGN and is a member of the Nasdaq Composite, so market participants often read this kind of note through both a company-specific and index-level lens.

Ad-hoc-News framed the report around the gap between the target price and the share's recent trading level, which is the key takeaway for today's stock in focus. No fresh earnings release or corporate action was included in the material provided, so the move is better understood as a valuation-and-sentiment story than as a reaction to new fundamentals.

Regeneron is a biotechnology company best known for specialty therapies and drug development, which means analyst targets tend to stay sensitive to pipeline updates, commercialization trends, and the durability of existing products. That broader setup helps explain why a price-target update can still attract attention even without a same-day headline from the company itself.

In practical terms, the market is being reminded that Regeneron still carries a meaningful analyst premium in published target work. If the stock remains below the consensus level, that can keep it on watchlists, but the report does not change the fact that the shares still need fresh operating evidence to close the gap.

Regeneron Pharma stock facts at a glance

• Name: Regeneron
• Industry: Biotechnology
• Headquarters: Tarrytown, New York, United States
• Core markets: Prescription medicines, specialty biologics, and drug development
• Revenue drivers: Ophthalmology, immunology, oncology, and other marketed therapies
• Listing: Nasdaq, ticker REGN; member of the Nasdaq Composite
• Trading currency: US dollars

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.